Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-A18 phase 3 trial of pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer
MOH_2020-06-28_009085Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing Chemoradiotherapy plus pembrolizumab with Chemoradiotherapy plus placebo (2 arms). Started May 2020; status: active, not recruiting.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on MOH_2020-06-28_009085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-28_009085.